Stock 600267 ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Zhejiang Hisun Pharmaceutical Co., Ltd.

Equities

600267

CNE0000013Z2

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-06-12 pm EDT 		5-day change 1st Jan Change
7.51 CNY -1.05% Intraday chart for Zhejiang Hisun Pharmaceutical Co., Ltd. +0.27% -19.76%
Jun. 04 Hisun Pharmaceutical's Veterinary Arm Gets Nod to Produce Fenbendazole Oral Suspension MT
May. 20 Hisun Pharma's Veterinary Arm Gets Approval to Register Amoxicillin and Clavulanate Potassium Dry Suspension MT

Summary

  • Overall, the company has poor fundamentals for a medium to long-term investment strategy.

Strengths

  • The company appears to be poorly valued given its net asset value.

Weaknesses

  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
  • The company is not the most generous with respect to shareholders' compensation.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. Stock Zhejiang Hisun Pharmaceutical Co., Ltd.
-19.76% 1.22B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+51.54% 795B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+41.74% 627B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-7.20% 350B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.67% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+7.48% 294B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+17.89% 245B
B+
ROCHE HOLDING AG Stock Roche Holding AG
+1.31% 222B
A+
NOVARTIS AG Stock Novartis AG
+12.16% 215B
B-
AMGEN INC. Stock Amgen Inc.
+3.64% 160B
C+
Investor Rating
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 600267 Stock
  4. Ratings Zhejiang Hisun Pharmaceutical Co., Ltd.